Jiangsu Jibeier Pharmaceutical Co Ltd (SHG:688566) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangsu Jibeier Pharmaceutical Co Ltd (688566)
Jiangsu Jibeier Pharmaceutical Co Ltd (SHG:688566) has a market capitalization of $725.78 Million (CN¥4.96 Billion) as of August 6, 2026. Listed on the SHG stock exchange, this China-based company holds position #10335 globally and #2745 in its home market, demonstrating a 4.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Jibeier Pharmaceutical Co Ltd's stock price CN¥24.87 by its total outstanding shares 199430865 (199.43 Million). See Jiangsu Jibeier Pharmaceutical Co Ltd capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Jiangsu Jibeier Pharmaceutical Co Ltd Market Cap History: 2020 to 2026
Jiangsu Jibeier Pharmaceutical Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $721.80 Million to $725.78 Million (-8.44% CAGR).
Jiangsu Jibeier Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Jibeier Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.90x
Jiangsu Jibeier Pharmaceutical Co Ltd's market cap is 0.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.37x
Jiangsu Jibeier Pharmaceutical Co Ltd's market cap is 3.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $721.80 Million | $565.97 Million | $129.72 Million | 1.28x | 5.56x |
| 2021 | $644.71 Million | $509.69 Million | $114.90 Million | 1.26x | 5.61x |
| 2022 | $621.22 Million | $654.73 Million | $154.67 Million | 0.95x | 4.02x |
| 2023 | $916.05 Million | $860.93 Million | $219.09 Million | 1.06x | 4.18x |
| 2024 | $653.70 Million | $896.53 Million | $219.33 Million | 0.73x | 2.98x |
| 2025 | $871.11 Million | $964.93 Million | $258.67 Million | 0.90x | 3.37x |
Competitor Companies of 688566 by Market Capitalization
Companies near Jiangsu Jibeier Pharmaceutical Co Ltd in the global market cap rankings as of August 6, 2026.
Key companies related to Jiangsu Jibeier Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #541 globally with a market cap of $49.98 Billion USD ( CN¥341.53 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #551 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #541 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.98 Billion | CN¥53.54 |
| #551 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $44.04 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.20 |
Jiangsu Jibeier Pharmaceutical Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Jiangsu Jibeier Pharmaceutical Co Ltd's market cap moved from $721.80 Million to $ 725.78 Million, with a yearly change of -8.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥725.78 Million | -16.68% |
| 2025 | CN¥871.11 Million | +33.26% |
| 2024 | CN¥653.70 Million | -28.64% |
| 2023 | CN¥916.05 Million | +47.46% |
| 2022 | CN¥621.22 Million | -3.64% |
| 2021 | CN¥644.71 Million | -10.68% |
| 2020 | CN¥721.80 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Jiangsu Jibeier Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $725.78 Million USD |
| MoneyControl | $725.78 Million USD |
| MarketWatch | $725.78 Million USD |
| marketcap.company | $725.78 Million USD |
| Reuters | $725.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more